Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for.
PureTech Health plc – Half-Year Report streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival. | May 3, 2023
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous